10-KPeriod: FY2013

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2013

Filed February 11, 2014For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. presented its 2013 annual report, highlighting significant progress in its core focus area: cystic fibrosis (CF). The company successfully launched and is expanding the reach of KALYDECO (ivacaftor) for CF patients with the G551D mutation. Vertex is actively pursuing label expansions for KALYDECO to include patients with other CFTR gene mutations and is also advancing combination therapies with lumacaftor (VX-809) and ivacaftor for the prevalent F508del mutation, with Phase 3 data expected in mid-2014. However, the company is facing challenges in its Hepatitis C (HCV) business, with INCIVEK revenues declining significantly due to increased competition. Vertex has also recorded substantial intangible asset impairment charges related to its HCV drug candidates, leading to a net loss for the year. Despite these setbacks, Vertex maintains a strong cash position and continues to invest heavily in research and development, particularly in CF, aiming to provide transformative treatments for serious diseases.

Financial Highlights

49 data points
Beta

Revenue

$1.21B

92.7% Gross Margin

Net Income

-$445.03M

-36.7% Net Margin

EPS (Diluted)

$-1.98

Total Assets

$2.32B

Cash & Equivalents

$569.30M

Free Cash Flow

-$112.06M

Financial Statements
Beta
Revenue$1.21B
Cost of Revenue$88.98M
Gross Profit$1.12B
R&D Expenses$882.10M
SG&A Expenses$356.19M
Operating Expenses$1.82B
Operating Income-$610.01M
Net Income-$445.03M
EPS (Basic)$-1.98
EPS (Diluted)$-1.98
Shares Outstanding (Basic)224.91M
Shares Outstanding (Diluted)224.91M

Key Highlights

  • 1Vertex Pharmaceuticals achieved significant revenue growth for KALYDECO (ivacaftor) in 2013, its primary CF therapy, and is actively seeking to expand its approved indications.
  • 2The company is progressing with Phase 3 clinical trials for the combination of lumacaftor and ivacaftor for the F508del mutation in cystic fibrosis, with expected data in mid-2014 and potential regulatory submissions in the second half of 2014.
  • 3The company reported a substantial decline in INCIVEK (telaprevir) revenues, a drug for Hepatitis C, due to increased market competition, leading to a strategic reduction in promotion and support.
  • 4Vertex recorded significant intangible asset impairment charges totaling $663.5 million in 2013, primarily related to its HCV drug development candidates VX-222 and VX-135.
  • 5The company experienced a net loss of $445.0 million in 2013, a significant increase from the $107.0 million net loss in 2012, largely driven by impairment charges and the decline in INCIVEK sales.
  • 6Vertex has a strong cash position with approximately $1.47 billion in cash, cash equivalents, and marketable securities as of December 31, 2013, providing a solid financial foundation for ongoing R&D.
  • 7The company is also advancing VX-661, another investigational CFTR corrector, in Phase 2 clinical development for cystic fibrosis.

Frequently Asked Questions

Vertex Pharmaceuticals' primary focus is on the development and commercialization of therapies for cystic fibrosis (CF). KALYDECO (ivacaftor) is its key revenue driver in this area, with ongoing efforts to expand its patient population and indications. The company's Hepatitis C (HCV) drug, INCIVEK, has seen declining revenues due to market competition.

Vertex is advancing the combination therapy of lumacaftor (VX-809) and ivacaftor for patients with the F508del mutation, the most common CF mutation. Phase 3 trial data is expected in mid-2014, with potential regulatory submissions in the latter half of the year. The company is also exploring label expansions for KALYDECO to cover other CFTR gene mutations and is developing VX-661, another CFTR corrector, in combination with ivacaftor.

Vertex is facing significant challenges in its HCV business due to intense market competition, which has led to a substantial decline in INCIVEK revenues. This downturn, coupled with a strategic decision to reduce promotion for INCIVEK, and the recognition of substantial intangible asset impairment charges ($663.5 million) related to its HCV drug candidates, has contributed to a net loss for the fiscal year 2013.

Vertex maintained a strong cash position as of December 31, 2013, with approximately $1.47 billion in cash, cash equivalents, and marketable securities. Despite the net loss in 2013 and the decline in HCV revenues, the company continues to invest heavily in R&D, particularly in CF, supported by its solid financial standing. The outlook for future revenue growth is heavily dependent on the success of its CF pipeline, especially the lumacaftor/ivacaftor combination.